Kurma Partners closed a €215M venture capital fund, described as its fourth and largest, targeting disruptive therapeutic solutions. The report notes prior Kurma exits including acquisitions of Corlieve Therapeutics, Emergence Therapeutics and Amolyt Pharma. For early-stage biotech builders, the closing signals continued appetite for therapeutics-focused investing in Europe and may shape follow-on capacity for portfolio companies seeking clinical progression and partnerships.